Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Immuneering (Nasdaq: IMRX) has appointed Dr. Thomas J. Schall as Chairman of the Board of Directors. Dr. Schall, who joined the board in March 2024, brings over 30 years of leadership in drug discovery and development, most notably as founder and CEO of ChemoCentryx, which was acquired by Amgen for $4 billion in 2022.
The appointment comes as Immuneering prepares to announce updated data from its phase 2a study of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025, with additional presentation at the PanCAN Annual Scientific Summit. The strategic timing of Dr. Schall's appointment signals the company's preparation for pivotal studies, registration filings, and commercialization plans.
Immuneering (Nasdaq: IMRX) ha nominato il dottor Thomas J. Schall presidente del consiglio di amministrazione. Il Dr. Schall, entrato nel consiglio nel marzo 2024, vanta oltre 30 anni di leadership nel campo della scoperta e sviluppo di farmaci, in particolare come fondatore e CEO di ChemoCentryx, che è stataacquisita da Amgen per $4 miliardi nel 2022.
L'incarico arriva mentre Immuneering si prepara a pubblicare dati aggiornati dal proprio studio di fase 2a atebimetinib + mGnP in pazienti con cancro pancreatico all'inizio di prima linea, il 25 settembre 2025, con una presentazione aggiuntiva al PanCAN Annual Scientific Summit. Il timing strategico della nomina di Dr. Schall segnala la preparazione dell'azienda per studi pivotal, presentazioni per l'approvazione e piani di commercializzazione.
Immuneering (Nasdaq: IMRX) ha designado al Dr. Thomas J. Schall como presidente del consejo de administración. El Dr. Schall, que se unió al consejo en marzo de 2024, aporta más de 30 años de liderazgo en descubrimiento y desarrollo de fármacos, destacando como fundador y CEO de ChemoCentryx, que fue adquirida por Amgen por $4 mil millones en 2022.
El nombramiento llega mientras Immuneering se prepara para anunciar datos actualizados de su ensayo de fase 2a de atebimetinib + mGnP en pacientes con cáncer de páncreas en primera línea, el 25 de septiembre de 2025, con una presentación adicional en la PanCAN Annual Scientific Summit. El momento estratégico de la designación de Schall señala la preparación de la empresa para estudios clave, presentaciones para registro y planes de comercialización.
Immuneering(Nasdaq: IMRX)는 이사회 의장으로 Dr. Thomas J. Schall을 임명했습니다. 2024년 3월 이사회에 합류한 Schall 박사는 약물 발견 및 개발에서 30년이 넘는 리더십을 보유하고 있으며, 특히 ChemoCentryx의 창립자이자 CEO로서 2022년 Amgen이 $40억에 인수했습니다.
이번 임명은 Immuneering이 1차 치료 췌장암 환자들을 대상으로 한 atebimetinib + mGnP의 2a상 데이터 업데이트를 2025년 9월 25일에 발표하고 PanCAN 연례 과학 정상회의에서 추가 발표를 준비하는 시점과 맞물려 있습니다. Schall 박사의 임명은 회사가 결정적 연구, 등록 제출, 상용화 계획을 준비하고 있음을 시사합니다.
Immuneering (Nasdaq: IMRX) a nommé Dr. Thomas J. Schall président du conseil d'administration. Le Dr Schall, entré au conseil en mars 2024, apporte plus de 30 ans de leadership dans la découverte et le développement de médicaments, notamment en tant que fondateur et PDG de ChemoCentryx, qui a été rachetée par Amgen pour $4 milliards en 2022.
Cette nomination intervient alors qu Immuneering se prépare à annoncer des données mises à jour de son essai Phase 2a atebimetinib + mGnP chez des patients atteints d'un cancer du pancréas en première ligne le 25 septembre 2025, avec une présentation supplémentaire au PanCAN Annual Scientific Summit. Le choix stratégique de nommer le Dr Schall signale la préparation de l'entreprise pour des études pivotales, des dépôts d'enregistrement et des plans de commercialisation.
Immuneering (Nasdaq: IMRX) hat Dr. Thomas J. Schall zum Vorsitzenden des Aufsichtsrats ernannt. Dr. Schall, der dem Vorstand im März 2024 beigetreten ist, bringt über 30 Jahre Führungserfahrung in der Wirkstoffforschung und -entwicklung mit, insbesondere als Gründer und CEO von ChemoCentryx, das 2022 von Amgen für 4 Milliarden USD übernommen wurde.
Die Ernennung erfolgt, während Immuneering sich darauf vorbereitet, aktualisierte Daten aus seiner Phase-2a-Studie von Atebimetinib + mGnP bei Erstlinien-Pankreaskarzinom-Patienten am 25. September 2025 bekanntzugeben, mit weiterführender Präsentation auf dem PanCAN Annual Scientific Summit. Der strategische Zeitpunkt der Ernennung von Dr. Schall signalisiert die Vorbereitung des Unternehmens auf pivotale Studien, Zulassungsanträge und Markteinführungspläne.
عَيّنت Immuneering (بورصة ناسداك: IMRX) الدكتور توماس ج. شال رئيساً لمجلس الإدارة. انضم الدكتور شال إلى المجلس في مارس 2024، وهو يجلب أكثر من 30 عامًا من القيادة في اكتشاف وتطوير الأدوية، لا سيما كونه المؤسس والمدير التنفيذي لشركة ChemoCentryx، التي استحوذت عليها أمجين مقابل 4 مليارات دولار في 2022.
يأتي هذا التعيين بينما تستعد Immuneering للإعلان عن بيانات مُحدّثة من دراستها المرحلة 2أ لدواء atebimetinib + mGnP في مرضى سرطان البنكرياس في الخط الأول في 25 سبتمبر 2025، مع عرض إضافي في قمة PanCAN العلمية السنوية. يشير التوقيت الاستراتيجي لتعيين الدكتور شال إلى استعداد الشركة لدراسات محورية وتقديم طلبات التسجيل وخطط التسويق.
Immuneering（纳斯达克股票代码：IMRX）已任命 Thomas J. Schall 博士 为董事会主席。Schall 博士于 2024 年 3 月加入董事会，拥有超过 30 年的领导经验，在药物发现与开发领域尤为突出，曾是 ChemoCentryx 的创始人兼 CEO，该公司于 2022 年被 Amgen 以 40 亿美元 收购。
此次任命正值 Immuneering 准备公布其 2a 期研究 atebimetinib + mGnP 在一线胰腺癌患者中的更新数据，该数据将于 2025 年 9 月 25 日公布，并在 PanCAN 年度科学峰会上进行额外披露。Schall 博士的任命在战略上表明公司正在为关键研究、注册申报和商业化计划做准备。
- Appointment of highly experienced Chairman with proven track record of $4B exit at ChemoCentryx
- Strategic timing ahead of phase 2a data announcement for lead program atebimetinib
- Company positioning for late-stage development and potential commercialization
- None.
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors.
Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly
“Tom’s appointment comes at a pivotal time for Immuneering,” said Ben Zeskind, Ph.D., CEO of Immuneering. “His deep expertise in building companies around first-in-class therapies—and navigating the complex path from early science to regulatory approval to commercialization—will be instrumental as we advance our lead program, atebimetinib, through late-stage development. His insight and leadership will be critical to realizing the full impact of our science for patients.”
Immuneering is set to announce updated data with 9 months median follow up from its ongoing phase 2a study of first-line pancreatic cancer patients treated with atebimetinib + mGnP, on September 25 and at the upcoming Pancreatic Cancer Action Network (PanCAN) Annual Scientific Summit on September 28.
Dr. Schall has served on Immuneering’s Board of Directors since March 2024 and brings to the Chairmanship a unique combination of scientific vision, operational discipline, and regulatory acumen. His appointment signals the company’s readiness to enter a new phase of execution as it prepares for pivotal studies, registration filings, and ultimately commercialization.
“I’ve spent my career working to develop medicines that make a real difference in patients’ lives—and that’s exactly what Immuneering is doing,” said Dr. Schall. “The progress this team has made is remarkable, and I’m honored to serve as Chairman at such a strategically important moment. I believe Immuneering has the potential to redefine what patients and physicians expect from cancer therapies.”
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of Deep Cyclic Inhibitors, including atebimetinib, alone or in combination with other agents, including modified Gemcitabine/nab-paclitaxel (mGnP), the pivotal timing of Dr. Schall’s appointment, initiation of a pivotal trial and related patient dosing; the ability of targeting MEK to deliver a more durable benefit; the timing and content of future data releases and presentations; and the timing for the initiation of additional atebimetinib clinical trial combination arms.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Carson Creehan
817-412-1096
carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/193b6211-e88e-4355-853c-ec51b35c86f6
FAQ
Who is the new Chairman of Immuneering (IMRX)?
What is Dr. Thomas Schall's experience in biotech?
When will Immuneering (IMRX) announce its phase 2a pancreatic cancer study results?
What is Immuneering's (IMRX) lead drug candidate?
When did Dr. Schall join Immuneering's Board of Directors?
